INO — Inovio Pharmaceuticals, Inc.

Summary of Inovio's Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Operating Expenses: Decreased by 22% year-over-year to $21.2 million in Q3 2025, down from $27.3 million in Q3 2024.
• Net Loss: Increased to $45.5 million, or $0.87 per share, primarily due to a $22.5 million noncash loss on fair value adjustments related to warrant liabilities. However, the net loss from operations before other items decreased by 22% to $21.2 million.
• Cash Position: Ended the quarter with $50.8 million in cash and equivalents, down from $94.1 million at the end of 2024. Estimated cash runway extends into Q2 2026.

2. Strategic Updates and Business Highlights:

• BLA Submission: Successfully completed the rolling submission of the Biologics License Application (BLA) for INO-3107, with expectations for FDA file acceptance by year-end 2025 and a potential PDUFA date in mid-2026.
• Commercial Strategy: Preparing for a swift launch of INO-3107, which is positioned as a preferred treatment for recurrent respiratory papillomatosis (RRP) due to its favorable clinical results and tolerability.
• Pipeline Advancements: Positive proof-of-concept data for DMAb technology published in Nature Medicine, and upcoming presentations on DPROT technology at the World Federation of Hemophilia Global Forum.

3. Forward Guidance and Outlook:

• Regulatory Milestones: Anticipate FDA acceptance of BLA submission by the end of 2025 and a potential approval in mid-2026.
• Commercial Readiness: Actively advancing market research, pricing strategies, and operational preparations for the launch of INO-3107.
• Long-term Potential: Continued focus on advancing other pipeline candidates, including INO-3112 and INO-5401, post-3107 launch.

4. Bad News, Challenges, or Points of Concern:

• Increased Net Loss: The significant increase in net loss due to noncash adjustments raises concerns about financial stability.
• Cash Burn Rate: Projected operational cash burn of approximately $22 million for Q4 2025, which could impact future funding needs.
• Competitive Landscape: The recent launch of Precigen's Papzimeos poses a competitive challenge, although management believes INO-3107's differentiated profile will allow it to capture market share.

5. Notable Q&A Insights:

• Market Entry Timing: Management expects limited penetration of Papzimeos into the market before INO-3107's potential approval, suggesting a favorable entry point for their product.
• Label Differentiation: INO-3107 may have a broader label compared to Papzimeos, particularly due to the absence of a requirement for minimal residual disease surgeries during treatment.
• Sales Force Preparedness: Plans are in place for a sales force and medical science liaisons to engage with healthcare providers prior to approval, ensuring a quick market entry.
• Cross-Reactivity Concerns: No anticipated cross-reactivity issues for patients switching from Papzimeos to INO-3107, although complete treatment regimens will be necessary for effectiveness.

Overall, Inovio is positioned for a significant milestone with the potential approval of INO-3107, while navigating financial challenges and competitive pressures in the market.